What Are Psychedelic Drugs? Understanding Therapeutic Psychedelics for Mental Health

Psychedelic drugs are substances that temporarily alter perception, mood, emotions, and cognition. A growing body of research is evaluating specific psychedelic-assisted approaches for conditions including depressive disorders, PTSD, certain substance use disorders, and psychological distress associated with serious or life-threatening illness. These treatments remain an evolving area of medicine, and the strength of evidence varies by substance, condition, and treatment protocol.

When these substances are used or studied in a clinical setting, they should not be framed as standalone solutions. Psychedelic-assisted medical treatment typically includes eligibility screening, preparation, supervised administration, follow-up, and integration appropriate to the treatment model.

At The Pearl Institute, our care model pairs medically supervised psychedelic-assisted treatment with preparation, appropriately trained professionals, and ongoing integration. Integration is a structured part of care, not an optional afterthought.

What Are Psychedelic Drugs?

“Psychedelic” describes a varied group of substances rather than one mechanism. Classic psychedelics such as psilocybin and LSD primarily act through serotonin 2A receptors; ketamine primarily affects glutamatergic signaling through NMDA-receptor antagonism; and MDMA has a distinct pharmacologic profile that increases serotonin and other monoamine signaling. These differences matter for safety, evidence, and clinical use.

Researchers are studying specific psychedelic-assisted protocols for potential uses such as:

Major depressive disorder, including treatment-resistant depression
PTSD
Alcohol use disorder
Tobacco use disorder
Psychological distress associated with serious or life-threatening illness
Other conditions in early-stage clinical research

Most clinical studies evaluate the medicine within a broader protocol that may include screening, preparation, supervised dosing, psychological support, and integration. Because these components are usually studied together, research has not yet established how much each component independently contributes to outcomes.

Psychedelic Therapy Is More Than the Medicine

One of the biggest misconceptions about psychedelic therapy is that healing comes simply from taking a psychedelic substance.

In regulated research and appropriately licensed clinical care, a high-quality psychedelic-assisted treatment program is typically built around several essential components:

A comprehensive medical and psychological evaluation
Careful preparation before treatment
Professionally supervised medicine sessions
Ongoing integration therapy afterward

Together, these stages are designed to support safety, help patients process their experiences, and explore how clinically relevant insights might be applied in daily life.

A profound experience by itself does not guarantee a therapeutic benefit or durable change.

Why Integration Is a Core Part of Treatment

If there's one concept everyone considering psychedelic therapy should understand, it's integration.

Integration is the structured process of reflecting on a psychedelic experience, monitoring concerns that emerge afterward, and exploring how relevant insights might be applied in everyday life. It is commonly included in psychedelic-assisted treatment protocols, but researchers are still determining which integration approaches improve outcomes and for whom.

When integration is delivered as psychotherapy, patients should work with appropriately licensed and trained clinicians. Depending on the treatment plan, sessions may help patients:

Process emotional experiences
Better understand personal insights
Develop healthier coping strategies
Build new habits and behaviors
Create a plan for continued growth

After a psychedelic experience, some people may need help making sense of difficult emotions, unexpected reactions, or new perspectives. Thoughtful follow-up and integration can provide a structured setting for that work, although its independent contribution to clinical outcomes has not yet been established.

At The Pearl Institute, integration is not treated as an optional add-on. It is a foundational part of our care model because clinical support and follow-up extend beyond the medicine session itself. Click here to read more on why integration is so important

Which Psychedelic Medicines Are Used or Studied in Clinical Care?

Not every psychedelic is used in the same way, and research findings for one substance or condition should not be generalized to another. Availability also differs: some drugs may be used legally under specific medical rules, while others are limited to authorized research or regulated state programs.

Ketamine

Ketamine is an FDA-approved anesthetic that is sometimes prescribed off-label for psychiatric conditions, including treatment-resistant depression; ketamine itself is not FDA-approved for any psychiatric disorder. Esketamine nasal spray is FDA-approved for specific depression indications under required safety controls. Ketamine is often discussed alongside psychedelics because it can produce altered states, but it is not a classic psychedelic.

Clinical studies support rapid antidepressant effects from ketamine in some patients, but response is not universal and benefits may require ongoing treatment. Psychotherapy and integration may be included in some care models, but their added benefit has not been established for every ketamine protocol.

Psilocybin

Psilocybin is a naturally occurring compound found in certain mushroom species. Controlled studies and systematic reviews report promising short-term results for depressive disorders, with additional research exploring substance use disorders and psychological distress associated with serious or life-threatening illness. Larger and longer-term studies are still needed.

Psilocybin remains one of the most actively studied psychedelic medicines. It is not FDA-approved for psychiatric treatment and, outside authorized research or applicable regulated programs, access remains restricted under federal and state law.

MDMA

Unlike classic psychedelics, MDMA has a distinct pharmacologic profile and may increase emotional openness and social connection. Clinical trials of MDMA combined with a structured psychological intervention for PTSD have reported encouraging results, but MDMA is not FDA-approved for PTSD or any other medical indication.

As with other psychedelic therapies, the medicine is only one part of a carefully designed therapeutic process.

Emerging Psychedelic Medicines

Researchers are also studying compounds such as LSD, DMT, and ibogaine for potential therapeutic applications. These substances are investigational, and their evidence bases differ substantially. Ibogaine also carries potentially serious cardiac risks. Further controlled research is needed to clarify safety, effectiveness, dosing, and appropriate clinical use.

Who May Benefit from Psychedelic Therapy?

Depending on the substance, diagnosis, applicable law, and clinical evaluation, a psychedelic-assisted approach may be considered for some people who have not experienced adequate relief from established treatments. Interest alone does not determine eligibility, and many uses remain investigational.

Conditions evaluated in clinical research include:

Major depressive disorder, including treatment-resistant depression
PTSD
Alcohol use disorder
Tobacco use disorder
Psychological distress associated with serious or life-threatening illness

Not everyone is an appropriate candidate. A qualified healthcare professional should review medical history, cardiovascular risk, current medications and possible interactions, substance use, pregnancy status when relevant, psychiatric history—including psychotic or bipolar-spectrum vulnerability—and treatment goals. Screening and monitoring requirements differ by medicine and route of administration.

Why Medical Supervision and Qualified Care Matter

Psychedelic medicines can cause intense psychological effects and may also affect blood pressure, heart rate, judgment, and coordination. Acute anxiety, confusion, or psychological distress can occur, and some adverse effects may emerge after the dosing session.

Care should be provided by appropriately licensed healthcare professionals who are trained for the specific medicine and who operate within applicable law, professional scope, and evidence-based safety standards. “Accredited” should be used only when a named, relevant accrediting body applies.

A high-quality psychedelic treatment program should include:

Thorough medical and mental health screening
Licensed healthcare professionals
Individualized treatment planning
Careful monitoring during treatment
Structured preparation sessions
Comprehensive integration support
Ongoing follow-up care

These safeguards are intended to reduce avoidable risk and support careful follow-up; they cannot guarantee a particular outcome.

The Pearl Institute's Approach to Psychedelic Healing

At The Pearl Institute, we view psychedelic medicine as one tool within a broader healing process—not a quick fix.

Our approach combines evidence-based care with compassionate support, ensuring that each patient receives individualized treatment designed around their unique needs and goals.

From your initial evaluation through preparation, medicine sessions, and integration, our team is committed to providing safe, ethical, and clinically grounded care every step of the way.

By pairing psychedelic medicine with preparation, clinical monitoring, and thoughtful integration, we aim to help patients examine treatment experiences and work toward durable, personally meaningful goals.

Frequently Asked Questions

Are psychedelic drugs legal?

Legal status depends on the substance, jurisdiction, indication, and treatment setting. Ketamine may be prescribed legally, including off-label, by qualified clinicians; esketamine has specific FDA-approved depression indications. Psilocybin and MDMA are not FDA-approved medical treatments and remain federally controlled, although authorized clinical research and some state-regulated programs may operate under specific rules.

Are psychedelic drugs safe?

These medicines carry psychological and physical risks and are not appropriate for everyone. Depending on the substance, risks can include acute anxiety or confusion, increases in blood pressure and heart rate, sedation or impaired coordination, medication interactions, misuse potential, and worsening of certain psychiatric symptoms. Proper screening, supervision, monitoring, and follow-up reduce risk but do not eliminate it.

Is ketamine considered a psychedelic?

Ketamine is often grouped within psychedelic medicine because of the altered states of consciousness it can produce and its use in psychedelic-assisted therapy, although it works differently from classic psychedelics like psilocybin or LSD.

Why is integration so important?

Integration provides structured time to process the experience, monitor emerging concerns, and explore whether insights can be applied safely in daily life. It is commonly included in clinical protocols and is a core part of The Pearl Institute's care model; however, research has not yet established its independent effect or a single best integration method.

Final Thoughts

Psychedelic drugs are an active and promising area of mental health research, particularly for some conditions that have not responded adequately to established treatments. Promising findings should be interpreted alongside study limitations, adverse effects, and the fact that many uses remain investigational.

The medicine itself is only one part of psychedelic-assisted medical treatment. Current clinical models commonly combine careful patient selection, preparation, supervised administration, follow-up, and meaningful integration, while researchers continue to study how each component contributes to safety and outcomes.

If you are considering psychedelic-assisted treatment, look for appropriately licensed professionals who practice within applicable law, explain the evidence and uncertainties, provide medical screening and monitoring, and include a clear plan for follow-up and integration.